We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 11, 2022

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
JAMA 2022 Oct 25;328(16)1595-1603, S Naggie, DR Boulware, CJ Lindsell, TG Stewart, N Gentile, S Collins, MW McCarthy, D Jayaweera, M Castro, M Sulkowski, K McTigue, F Thicklin, GM Felker, AA Ginde, CT Bramante, AJ Slandzicki, A Gabriel, NS Shah, LA Lenert, SE Dunsmore, SJ Adam, A DeLong, G Hanna, A Remaly, R Wilder, S Wilson, E Shenkman, AF Hernandez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading